PT-141 for Men: Studies and Label Warnings
Studies of PT-141 that enrolled only men, what they measured, and what is still unproven.
- Strongest evidence
- Human RCT
- Studies enrolling only men
- 3
- in our evidence file (PubMed search, 2 Oct 2026)
- FDA status
- FDA approved for HSDD (Vyleesi)
Studies that enrolled only men
Each row is a study whose participants were described as men only. Results from one sex are not evidence for the other. Studies of animals and cells are not included.
| Study | Design | Population | Dose | First outcome |
|---|---|---|---|---|
| The Journal of urology 2008, PMID 18206919 | Human RCT | Married men aged 28 to 59 with erectile dysfunction who did not respond to sildenafil | 10 mg | Positive clinical response in sildenafil non-responders: 51 (33.5%) of the bremelanotide group had positive clinical results versus 13 (8.5%) on placebo (p = 0.03). |
| International journal of impotence research 2004, PMID 14999221 | Human RCT | Healthy men and men with erectile dysfunction and inadequate response to Viagra (phase 1/2) | 0.3 to 10 mg healthy; 4 or 6 mg in ED patients | Erectile response (RigiScan): Erectile response was statistically significant versus placebo at both 4 mg and 6 mg in men with inadequate response to Viagra. |
| International journal of impotence research 2004, PMID 14963471 | Human RCT | Healthy men and Viagra-responsive men with mild-to-moderate ED | Not stated | Erectile response (RigiScan): Erectile response beat placebo at doses above 7 mg; first erection began in about 30 minutes. |
Peptides studied in men, compared
How strong is it?
A human randomized trial outweighs any number of animal studies. Animal and cell results show a mechanism worth testing, not that it works in people.
Why this page is about men's studies
MedlinePlus frames some conditions as affecting only men, and the studies below were run in men with erectile dysfunction rather than the condition the approved product treats.[8]
Trials that enrolled only men
The largest randomized 342 married men aged 28 to 59 with erectile dysfunction who did not respond to sildenafil to a 10 mg nasal spray or placebo.[1]
Its result: positive clinical results in 51 men on bremelanotide against 13 on placebo, with more drug-related adverse effects in the active group.[1]
A subcutaneous crossover study in men with erectile dysfunction used 4 mg and 6 mg doses against placebo and found a statistically significant erectile response at both.[2]
A nasal pharmacokinetic study in healthy men reported peak concentration and exposure rising with dose, with a mean half-life of 1.85 to 2.09 hours.[3]
What the label says about men
The approved product's label states it is not indicated for men.[9]
Other peptides people research for men
All peptides for men, comparedCommon questions
Has PT-141 been studied in men?
3 studies we summarise enrolled only men. Results from one sex are not evidence for the other.
Is PT-141 approved for men?
No: the only approved bremelanotide product is limited to premenopausal women, and the label says it is not indicated in men.[9]
What did the trials in men find about side effects?
Flushing and nausea were the most common adverse events in the nasal studies, and no clinically significant vital-sign, laboratory or ECG changes were seen.[3]
More on PT-141
Sources
- 1Salvage of sildenafil failures with bremelanotide: a randomized, double-blind, placebo controlled study.The Journal of urology · 2008PMID 18206919Accessed 2 Oct 2026
- 2Evaluation of the safety, pharmacokinetics and pharmacodynamic effects of subcutaneously administered PT-141, a melanocortin receptor agonist, in healthy male subjects and in patients with an inadequate response to Viagra.International journal of impotence research · 2004PMID 14999221Accessed 2 Oct 2026
- 3Double-blind, placebo-controlled evaluation of the safety, pharmacokinetic properties and pharmacodynamic effects of intranasal PT-141, a melanocortin receptor agonist, in healthy males and patients with mild-to-moderate erectile dysfunction.International journal of impotence research · 2004PMID 14963471Accessed 2 Oct 2026
- 4PubMed search: bremelanotide[tiab] OR "PT-141"[tiab] OR PT141[tiab] (114 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 5PubMed search: (bremelanotide[tiab] OR "PT-141"[tiab]) AND randomized controlled trial[pt] (14 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 6PubMed search: (bremelanotide[tiab] OR "PT-141"[tiab]) AND (half-life[tiab] OR pharmacokinetic*[tiab]) (7 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 7PubMed search: (bremelanotide[tiab] OR "PT-141"[tiab] OR PT141[tiab]) AND (erectile[tiab] OR men[tiab]) (20 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 8Official web pageOfficial web page · web page
- 9VYLEESI prescribing information (FDA label)FDA label, DailyMed · current labeldailymed.nlm.nih.govAccessed 2 Oct 2026
Found an error? Report a correction.